References
- Becerra A, Bellido D, Luengo A, Piedrola G, De Luis DA. Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. Clin Nutr 18, 319–322, 1999.
- Cheng H, Hu Y, Zhao H, Zhou G, Wang G, Ma C, Xu J. Exploring the association between triglyceride-glucose index and thyroid function. Eur J Med Res 28, 508, 2023.
- Delitala AP, Fanciulli G, Maioli M, Delitala G. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med 38, 17–24, 2017.
- Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol 52, 151–156, 2010.
- Isaila OM, Stoian VE, Fulga I, Piraianu AI, Hostiuc S. The relationship between subclinical hypothyroidism and carotid intima-media thickness as a potential marker of cardiovascular risk: a systematic review and a meta-analysis. J Cardiovasc Dev Dis 11, 98, 2024.
- Jabbar A, Pingitore A, Pearce SHS, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 14, 39–55, 2017.
- Martinez-Lopez D, Roldan-Montero R, Garcia-Marques F, Nunez E, Jorge I, Camafeita E, Minguez P, Rodriguez de Cordoba S, Lopez-Melgar B, Lara-Pezzi E, Fernandez-Ortiz A, Ibanez B, Valdivielso JM, Fuster V, Michel JB, Blanco-Colio LM, Vazquez J, Martin-Ventura JL. Complement C5 protein as a marker of subclinical atherosclerosis. J Am Coll Cardiol 75, 1926–1941, 2020.
- Poznyak AV, Litvinova L, Poggio P, Sukhorukov VN, Orekhov AN. Effect of glucose levels on cardiovascular risk. Cells 11, 3034, 2022.
- Rehberger Likozar A, Zavrtanik M, Sebestjen M. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options. Ann Med 52, 162–177, 2020.
- Sanchez-Garcia A, Rodriguez-Gutierrez R, Mancillas-Adame L, Gonzalez-Nava V, Diaz Gonzalez-Colmenero A, Solis RC, Alvarez-Villalobos NA, Gonzalez-Gonzalez JG. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol 2020, 4678526, 2020.
- Saric MS, Jurasic MJ, Budincevic H, Milosevic M, Kranjcec B, Kovacic S, Leskova J, Demarin V. The role of thyroid hormones in carotid arterial wall remodeling in women. Rom J Intern Med 60, 24–33, 2022.
- Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord 6, 299–304, 2008.
- Sulu C, Dedeoglu SE, Gonen B, Hepokur M, Guzel AN, Sahin S, Demir AN, Kara Z, Konukoglu D, Damci T. Gonin MS. Serum lipoprotein(a) is not associated with Graves’ ophthalmopathy. Metab Syndr Relat Disord 22, 69–76, 2024.
- Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol 21, 68, 2022.
- Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation 147, e93–e621, 2023.
- Wisnu W, Alwi I, Nafrialdi N, Harimurti K, Pemayun TGD, Jusman SWA, Santoso DIS, Harahap AR, Suwarto S,
- Subekti I. The differential effects of propylthiouracil and methimazole as Graves’ disease treatment on vascular atherosclerosis markers: a randomized clinical trial. Front Endocrinol (Lausanne) 12, 796194, 2021. Xu Z, Chen Y, Wang Y, Han W, Xu W, Liao X, Zhang T, Wang G. Matrix stiffness, endothelial dysfunction and atherosclerosis. Mol Biol Rep 50, 7027–7041, 2023.
- Zhang MZ, Zhao C, Xing XM, Lv J. Deciphering thyroid function and CIMT: a Mendelian randomization study of the U-shaped influence mediated by apolipoproteins. Front Endocrinol (Lausanne) 15, 1345267, 2024.
- Zhao C, Yu Y, Liu J, Lu G, Li T, Gao Y, Zhang J, Guo X. Diversity of complement activation in different thyroid diseases. Int Immunopharmacol 106, 108636, 2022.